glp-1 users need strength training to prevent muscle loss How While Taking Medications Expert-Approved Exercises to Prevent GLP-1

Galderma premieres positive interim results demonstrating the efficacy of its Injectable Aesthetics portfolio in addressing facial volume loss as a result of medication-driven weight loss Three-month interim data from first-of-its-kind trial demonstrate that the combination of Sculptra and Restylane Lyft or Contour effectively improved the facial aesthetic appearance of patients experiencing medication-driven weight loss with associated facial volume loss 1 A six-month extension study is ongoing to capture the combined and sustained effects of these treatments over time Galderma is well-positioned to support patients specific needs in this area, given its unique expertise in dermatology, including aesthetics, and its individualized treatment approach developed in close collaboration with healthcare professionals Zug, Switzerland January 14, 2025 Galderma announces positive first results from a trial designed to explore the benefits of Restylane Lyft or Contour in combination with Sculptra in patients with medication-driven weight loss with associated facial volume loss

Both trials suggest maintenance strategies, such as lower-dose injections or oral therapies, could offer patients more flexible, potentially more convenient options for sustaining weight loss after intensive treatment

Just reliable results in a box

Rybelsus (oral semaglutide) is an FDA-approved medication for adults with type 2 diabetes

However, the profound weight loss observed with GLP-1 RA treatment (as well as other approaches resulting in weight loss through appetite suppression, such as bariatric surgery) raises some concerns